Prescription drug · ANDA
acyclovir NDC 82804-245
Acyclovir 200 mg/1 · Capsule · Oral · Proficient Rx LP
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 82804-245-30 | 82804024530 | 30 CAPSULE in 1 BOTTLE (82804-245-30)Marketed from May 13, 2026 | |
| 82804-245-90 | 82804024590 | 90 CAPSULE in 1 BOTTLE (82804-245-90)Marketed from Sep 24, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- acyclovir
- Generic name (nonproprietary)
- acyclovir
- Active ingredients
- Acyclovir — 200 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Proficient Rx LP
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 204313
- Marketing start
- Listing expires
- Other FDA classes
- DNA Polymerase Inhibitors (Mechanism)Nucleoside Analog (EXT)
- Identifiers
- Product ID 82804-245_d3dc05d3-5ea8-4d12-8bc8-31ea6ba9c909SPL ID d3dc05d3-5ea8-4d12-8bc8-31ea6ba9c909SPL set ID d4729677-164b-41b8-bbc4-4e47346b0f72RxCUI 197310UNII X4HES1O11FUPC 0382804245901
- Pharmacologic class
- Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N482804024530followed by a unit qualifier and the quantityPackage 82804-0245-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Herpes Zoster Infections: Acyclovir capsules are indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir capsules are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Acyclovir capsules are indicated for the treatment of chickenpox (varicella).
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 204313
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| acyclovir | Acyclovir 200 mg/1 | CapsuleOral | Northwind Health Company, LLC | 51655-965 |
| acyclovir | Acyclovir 200 mg/1 | CapsuleOral | PD-Rx Pharmaceuticals, Inc. | 72789-536 |
| acyclovir | Acyclovir 200 mg/1 | CapsuleOral | Zydus Lifesciences Limited | 65841-829 |
| acyclovir | Acyclovir 200 mg/1 | CapsuleOral | REMEDYREPACK INC. | 70518-3436 |
| acyclovir | Acyclovir 200 mg/1 | CapsuleOral | A-S Medication Solutions | 50090-7216 |
| acyclovir | Acyclovir 200 mg/1 | CapsuleOral | Bryant Ranch Prepack | 71335-2261 |
| Acyclovir | Acyclovir 200 mg/1 | CapsuleOral | NuCare Pharmaceuticals,Inc. | 68071-2526 |
| acyclovir | Acyclovir 200 mg/1 | CapsuleOral | Viona Pharmaceuticals Inc | 72578-002 |